# Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT01019174** · PHASE1,PHASE2 · COMPLETED · sponsor: **Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH** · enrollment: 40 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01019174
- **Lead sponsor:** Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019174, "Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01019174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*